Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

REGENERAR

Financiado

IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATI...

IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION The central nervous system has a limited capacity for self-repair. Therefore, technologies to replace lost neurons after an injury, including stroke or neurodegenerative diseases, are of great need. The project REGENERAR aims to d... ver más

29/02/2028

UNIVERSIDADE DE CO...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

UNIVERSIDADE DE COIMBRA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 6 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-06

HORIZON-EIC-2023-PATHFINDEROPEN-01-01: EIC Pathfinder Open Scope:

I+D

Cerrada hace 1 año

0% 100% 100%

6 Participantes

UNIVERSIDADE DE COIMBRA

1.10M€ | Lider

Single Technologies AB

353.00K€ | Participante

HMGU

693.58K€ | Participante

SPI

153.13K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2010-22106 NUEVOS MODELOS CELULARES Y TERAPIAS PARA ENFERMEDADES NEUROL... 24K€ Cerrado

TARGETNMDs A novel and empowered TARGETed gene addition approach at a r... 2M€ Cerrado

FRATAXAV Pre-clinical validation of a novel gene therapy for a rare d... 75K€ Cerrado

EnhanceRegen Rewiring gene regulatory circuits to enhance central nervous... 2M€ Cerrado

inteRNAlizer Efficient, safe, and cost-efficient RNA delivery vehicles fo... 150K€ Cerrado

TREM2MEDS Towards the clinical implementation of TREM2 Microglia Engin... 2M€ Cerrado

Duración del proyecto: 52 meses Fecha Inicio: 2023-10-06
Fecha Fin: 2028-02-29

Líder del proyecto

UNIVERSIDADE DE COIMBRA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto The central nervous system has a limited capacity for self-repair. Therefore, technologies to replace lost neurons after an injury, including stroke or neurodegenerative diseases, are of great need. The project REGENERAR aims to develop a non-viral delivery formulation up to TRL4 for the delivery of an epigenetic reprogramming formulation to reprogram glial cells into neurons. The in vitro safety and targeting of the formulation will be tested against glial cells and organotypic cortical slice cultures. Several routes of administrations will be tested to enhance the accumulation of the formulation in the brain. In addition, the in vivo safety, elimination, targeting and epigenetic reprogramming will be evaluated. In addition, toxicological studies will be performed in GLP conditions to evaluate both in vivo systemic and local (brain) effects of the formulation. The development of the non-viral formulation will take in account the contributes of key stakeholders in the area of gene editing, health institutions, patient associations, among others. A roadmap will be developed for upscaling innovation to higher TRL´s upon the end of the action.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores